Sotrovimab Access and Reimbursement Information

Learn about sotrovimab access and information on reimbursement. See the box below for a directory of the information featured on this page.

For more complete information about access and reimbursement for sotrovimab, please access these essential guides 
 or contact 1-866-GSK-COVID (866-475-2684).

Product Availability

Sotrovimab is only available through AmerisourceBergen during the Emergency Use Authorization (EUA) period approved by the FDA. Sotrovimab is approved for infusion in appropriate patients as defined in the Sotrovimab Fact Sheet for Healthcare Providers.


GSK, with guidance from the National Infusion Center Association (NICA), has developed an in-depth resource entitled Detailed Guide for the Use of Sotrovimab.


Ordering from AmerisourceBergen

Sotrovimab is available for customers to purchase directly with AmerisourceBergen as the sole Specialty Distributor during the Emergency Use Authorization period. Customers can purchase directly by:


  • Placing purchase order through the customer ordering portal at
  • Calling AmerisourceBergen Customer Service at 1-800-746-6273 Monday through Thursday 7:00 AM to 6:30 PM, and Friday 7:00 AM to 6:00 PM CT or
  • Placing the purchase order through any of the AmerisourceBergen ordering platforms. Customers may search by product name, material item number, or NDC. For new customers please call AmerisourceBergen Customer Service or email


The sotrovimab material item number is 10258949. Please include the item number when placing your order.


Please allow 1 to 2 days for product arrival following order placement. For new customers, please allow up to 2 days for the initial order following receipt of the required customer documentation. For any additional information regarding orders, product availability, or access/log-in information, please email or contact AmerisourceBergen’s Customer Service Department.


Other available AmerisourceBergen customer service contacts


Phone numbers

ASD – 1-800-746-6273

Besse – 1-800-543-2111


Oncology Supply – 1-800-633-7555


Sites will be required to1:

  • Provide AmerisourceBergen with a board of pharmacy license or physician letter of authorization if not already on file 
  • Attest to their designated class of trade and that they will administer sotrovimab according to terms of the FDA-issued EUA


Additional information

  • Product availability may be subject to established criteria for minimum and maximum amounts based on previous orders and utilization history 
  • GSK and AmerisourceBergen will ensure that the authorized labeling (eg, Fact Sheets) will accompany the authorized sotrovimab. Please see most current Fact Sheet for Healthcare Providers and Fact Sheet for Patients, Parents and Caregivers
  • GSK and AmerisourceBergen will ensure that appropriate storage and cold chain is maintained until the product is delivered to healthcare facilities and/or healthcare providers
  • GSK and AmerisourceBergen will ensure that the terms of the sotrovimab EUA are made available to all relevant stakeholders (eg, U.S. government agencies, state and local government authorities, authorized distributors, healthcare facilities, healthcare providers) involved in distributing or receiving authorized sotrovimab
  • GSK will provide all relevant stakeholders a copy of the FDA Letter of Authorization and communicate any subsequent amendments that might be made to this letter of authorization and its authorized accompanying materials (eg, Fact Sheets)

GSK Customer Support

GSK Customer Support and Resources

GSK has established a dedicated team to help customers with medical, product, and disease state information, as well as reimbursement support and other resources, and to provide information regarding clinical trial programs. Customers can call the GSK COVID Contact Center directly Monday through Friday, 9:00 AM to 6:00 PM ET at 1-866-GSK-COVID (866-475-2684) or go to


HCP and healthcare settings should report all product quality claims directly to the GSK COVID Contact Center. For more information regarding GSK's Product Replacement Policies, please call the GSK Pharma Service Center at 1-800-877-1158 option 4 Monday through Friday, 8:00 AM to 6:00 PM ET.

Co-pay Assistance

GSK may be able to help eligible commercially insured patients with their out-of-pocket costs, subject to program rules and limitations. Please call the GSK COVID Contact Center at 1-866-GSK-COVID (866-475-2684) for questions regarding the co-pay program eligibility requirements and to find out how to enroll.


You can also learn more by accessing the GSK Co-pay Program for Sotrovimab Patients brochure and enrollment form below.



Access and Reimbursement

For more complete information on access and reimbursement for sotrovimab, download this guide:




The Centers for Medicare & Medicaid Services has released a set of toolkits for providers, states, and insurers to help the healthcare system prepare and assist in swiftly administering monoclonal antibodies once they become available during the public health emergency. These resources are designed to increase the number of providers that can administer the products and ensure adequate reimbursement for administration in Medicare. Medicare will publish codes and rates for administering new products as the FDA approves or authorizes each product. For more information on payment allowances and other related information for these products, review the Monoclonal Antibody COVID-19 Infusion page on



States and the federal government fund Medicaid and the Children’s Health Insurance Program (CHIP) jointly. The programs are administered by states according to federal requirements and comprehensive benefits offered to people who are determined eligible by states. For information on benefits offered in your state, where to access services, and how to apply for coverage, visit For additional information on the coverage of monoclonal antibody products to treat COVID-19, visit



The Health Resource and Service Administration (HRSA) is providing support to healthcare providers fighting the COVID-19 pandemic through the COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured Program. This program provides reimbursements on a rolling basis directly to eligible providers for claims that are attributed to the testing, treatment, and vaccine administration for COVID-19 for uninsured individuals. For more information, see FAQs for COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment and Vaccine Administration.


Reimbursement from commercial payers

Commercial payer reimbursement for sotrovimab will vary based on the payer, hospital system, region, and payer policy during the public health emergency. Reimbursement and administration for sotrovimab will be based on the patient’s health plan, coverage policy, and the provider's fee schedule. Please contact the reimbursement department for the patient's payer or health system with specific questions regarding billing and coverage.


  1. Overview of Direct Order Process for COVID-19 Therapeutics, Public Health Emergency. Accessed June 1, 2021.
  2. Medicare Monoclonal Antibody COVID-19 Infusion Program Instruction. Accessed May 14, 2021.
  3. The Children’s Health Insurance Program (CHIP). Accessed May 14, 2021.
  4. COVID-19 Claims Reimbursement To Health Care Providers And Facilities For Testing, Treatment, And Vaccine Administration For The Uninsured. Health Resources & Services Administration. Accessed May 14, 2021.

Contact Us

To learn more about COVID-19, visit the CDC and WHO websites.